Douglas A. Levine, MD, FACOG, FACS, will join the faculty of NYU Langone Medical Center as Director of the Division of Gynecologic Oncology at its Laura and Isaac Perlmutter Cancer Center and the Department of Obstetrics and Gynecology, effective May 15, 2016.
Douglas A. Levine, MD, FACOG, FACS
Dr. Levine brings an exceptional record of positive patient outcomes and a history of leadership and expertise in studying the most advanced diagnostics, treatments, and prevention approaches for those at risk or suffering from ovarian and endometrial cancers.
Dr. Levine joins NYU Langone from Memorial Sloan Kettering Cancer Center, where he served as Attending Physician and Head of the Gynecology Research Laboratory. Specifically, his studies helped bring greater focus on treating patients through individualized therapies based on genetics and risk factors. He served as a translational scientist on many national clinical trials determining what genomic alterations are associated with response to targeted therapies. There, he discovered universal mutations in SMARCA4 that drive small cell carcinoma of the ovary.
Dr. Levine has also been active within the National Institutes of Health–sponsored Cancer Genome Atlas project. He serves as Co-Chair of the Ovarian, Endometrial, and Uterine Carcinosarcoma Disease Working Groups and provides a translational focus to the genomic analyses of these projects.
In addition to these responsibilities, Dr. Levine is a member of the Scientific Advisory Committee of the Ovarian Cancer Research Fund. He has been awarded the American Congress of Obstetricians and Gynecologists Mentor Award; served as Co-Chair of the American Association for Cancer Research Special Conference on Ovarian Cancer; received the 2013 Foundation for Women’s Cancer Excellence in Ovarian Cancer Research Prize; and was recently named the Assistant Dean of the Department of Defense Ovarian Cancer Academy.
Dr. Levine completed medical school at the Mount Sinai School of Medicine and his residency in obstetrics and gynecology at Mount Sinai Medical Center. He then completed a gynecologic oncology fellowship at Memorial Sloan Kettering, in addition to 2 years of full-time laboratory research there. ■